drugset / Trial / NCT02630992

Reduced Clavulanate Formulation of Amoxicillin-Clavulanate in Children 6-23 Months With Acute Otitis Media

NCT02630992

Phase 3 Completed 112 enrolled Nader Shaikh
NaSingle-groupOpen-labelOther

Summary

To evaluate the safety profile of amoxicillin-clavulanate potassium containing a reduced concentration of clavulanate potassium, 600 mg/21.5 mg/5 mL (a ratio of 28:1), administered at 90/3.2 mg/kg/day (formulation 1) or at 80/2.85 mg/kg/day (formulation 2) in two divided doses for 10 days. Investigators will focus on the proportion of subjects who develop protocol-defined diarrhea and proportion who develop diaper dermatitis that occasions the prescription of antifungal medication.

Timeline

Start
2015-12
Primary completion
2016-12
Completion
2017-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified 80 mg/kg Oral
Subject Amoxicillin Other / unclassified 90 mg/kg Oral

Indications